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Sudden coronary death is a major cause of mortality in the United States today. 
As many as 199,000-386,000 (12) individuals may die suddenly each year, with 
the majority of these deaths resulting from ventricular fibrillation secondary to 
ischemic heart disease (64). This makes the management of ventricular rhythm 
disorders in patients with ischemic heart disease and the prevention of sudden 
coronary death a high priority for pharmaceutical research and drug development. 
While there are many drug agents currently available for the treatment and suppres- 
sion of chronic ventricular arrhythmias, no studies have been conducted to date as 
to the effectiveness of suppression of ventricular arrhythmias in reducing mortality 
due to sudden coronary death. In addition, no currently available antiamhythmic 
agent has the combined properties of low toxicity and proven efficacy for the 
prevention of sudden coronary death which is most often due to ventricular fibril- 
lation. 
One group of drugs that has been studied for its ability to prevent sudden death 
is the beta-blockers. Both alprenolol(1,2,86) and practolol(48,49) have been found 
to reduce mortality when given to patients following a myocardial infarction. How- 
ever, in other studies, practolol (7), propranolol (8,54,84), atenolol (84), and ox- 
prenolol (85) have been reported to be ineffective in reducing the incidence of 
sudden coronary death in post-myocardial infarction patients. It should be empha- 
sized that in none of the above studies was the relationship between the suppression 
of ventricular arrhythmias and sudden death examined. 
Recently, there has been new interest in the beta-blockers with the publication 
of a report on timolol (55). This agent was shown to reduce both total mortality 
and mortality due to sudden cardiac death, once again suggesting that beta-adre- 
nergic blockade may protect patients at risk of sudden coronary death. However, 
the interruption of adrenergic support to the heart by the general use of beta- 
adrenergic blocking agents may not be without hazard in those patients who require 
a degree of cardiac inotropic and chronotropic support during the acute phase of 
myocardial infarction. Such patients may be subject to a higher incidence of car- 
diogenic shock and bradyarrhythmias. Furthermore, beta-adrenergic receptor block- 
ade might preclude the successful use of inotropic agents such as norepinephrine 
or dopamine. Other limitations to the use of beta-receptor blocking agents would 
be those patients with obstructive airway disease and those with heart failure. 
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Since beta-adrenergic receptor blockade may not be essential for the antiar- 
rhythmic actions of “membrane stabilizing” beta-blockers such as propranolol, one 
approach to the above problem would be to design a pharmacologic agent with the 
beneficial electrophysiological properties of the beta-adrenergic blocking agents, 
but without the ability to inhibit the beta-adrenergic receptor. 
This chapter describes the electrophysiologic and pharmacologic properties of 
pranolium (fN,N-dimethyl- 1 -isopropylamino-3-( 1 -naphthyloxy)-propran-2-01]); UM- 
272, SC-27761 (Fig. l), the dimethyl quaternary derivative of propranolol. Pran- 
olium has been demonstrated to be an effective antiarrhythmic agent when tested 
against a variety of experimentally induced cardiac arrhythmias while possessing 
no beta-adrenergic blocking activity nor showing any local anesthetic activity. In 
addition, data presented in this chapter suggest that pranolium may be an effective 
agent in the treatment of sudden coronary death. 
ZN VZTRO ELECTROPHYSIOLOGY 
The only microelectrode study published to date on the electrophysiology of 
pranolium is that of Rosen et al. (67). These workers found pranolium’s electro- 
physiologic properties to closely resemble those of propranolol in canine Purkinje 
fibers. At a concentration of M, pranolium produced a time-dependent decrease 
in action potential amplitude and in the maximum rate of depolarization (V,,), a 
slight decrease in resting membrane potential, and a shortening of the action potential 
duration (APD) as measured at 50% repolarization (Fig. 2). Propranolol produced 
the same qualitative alterations in the action potential of similar or greater magnitude 
than pranolium and in a shorter time period. The effects of pranolium were also 
dose related, as and lod7 M pranolium exerted lesser effects on the action 
potential than the M concentration. Pranolium, lo-* M ,  also decreased V, 
at all levels of membrane potential (Fig. 3), and this was related to a 1.50-fold 
increase in conduction time. The effective refractory period (ERP) was decreased 
slightly by pranolium, but APD was decreased to a greater degree than ERP, 
resulting in an increase in the ERP relative to the APD. This also resulted in an 
increase in the activation voltage of the earliest propagated premature beat (that 
beat occurring just at the ERP) despite the fact that repolarization was more fully 
complete at the time of the earliest premature beat. 
Automaticity in canine Purkinje fibers was reduced by pranolium via a reduction 
in the slope of phase 4 depolarization. However, pranolium, M, was not able 
to block the increase in spontaneous rate due to the addition of 8pg of epinephrine 
to the bathing medium. In contrast, propranolol at 5 x M was fully effective 
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FIG. 2. Effects of pranolium, M, and propranolol, M, on action potential character- 
istics. Vertical axis: action potential amplitude, resting membrane potential, Vmx, and duration 
to 50% repolarization. Horizontal axis: time. Mean * SE of eight experiments with pranolium 
and six experiments with propranolol. (K+]o = 4 mM. Temp. 3637°C; cycle length BOO msec. 
(From Rosen et al., ref. 67, with permission.) 
in antagonizing the increase in rate produced by epinephrine, suggesting that pran- 
olium lacks beta-adrenergic blocking properties. 
Microelectrode data from our laboratory (unpublished observations) tend to sup- 
port the findings of Rosen et al. (67), at least in so far as pranolium's ability to 
decrease V,,,,,. Figure 4 shows a control recording of an action potential and its 
first derivative from canine ventricular muscle both before and after 5 x M 
of pranolium. Note that the presence of pranolium shortened the APD and decreased 
Vmm. However, in our study, M pranolium had little effect on canine Purkinje 
fiber APD, but produced a definite increase in the ERP (Fig. 5) .  The reason for 
this discrepancy in the effect of pranolium on ERP is not certain, but may be the 
result of the different concentrations used versus M). The concentration 
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FIG. 3. Effects of pranolium on membrane responsiveness. Temp. 37°C. Vertical axis: V ,  
(voltsfsec). Horizontal axis: membrane potential (millivolts). Perfusion period, 20 rnin. (From 
Rosen et at., ref. 67, with permission.) 
of M used in our laboratory more realistically reflects the tissue concentration 
of pranolium found in the heart after an intravenous dose of 5 mg/kg. This is an 
effective antiarrhythmic dose of pranolium and results in a myocardial concentration 
of 34-36 pg/g tissue (see section below on Pharmacokinetics). In addition, the 
overwhelming amount of in vivo electrophysiologic data indicate that pranolium 
prolongs ERP (see below). For this reason it is our conclusion that, based on 
microelectrode studies, pranolium's major electrophysiologic effects are to decrease 
V,,, and conduction velocity and increase refractoriness. 
An ex vivo study reported by Dresel and Potter (13) found pranolium to decrease 
conduction velocity in atria, AV node, and the ventricles of isolated blood perfused 
dog hearts. Both propranolol and pranolium (but not practolol) produced dose- 
related increases in the minimal conduction time (MCT) of the AV node in response 
to late premature stimuli. The increase in conduction times noted with the two 
larger doses of pranolium (2-4 mg/kg) was not statistically significant due to the 
large variability among hearts. At 1 mglkg pranolium produced, however, a sig- 
nificant increase in conduction time. At 1, 2, and 4 mglkg pranolium produced, 
on the average, an increase in AV conduction time. In addition, pranolium produced 
a nonparallel shift to the Tight of the curve relating AV conduction to the degree 
of prematurity of extrasystoles (ACT). This means that in the presence of pranolium 
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FIG. 4. Transmembrane recordings from a canine ventricular muscle cell (lower traces) and 
the corresponding dvldt of phase 0 (upper traces) before and after administration of pranolium. 
Note shortening of action potential and reduction in maximum dv/df. 
(2 mg/kg), late but not early extrasystoles were conducted at a slower rate through 
the AV node than in the absence of pranolium. In this respect, pranolium resembles 
methyl lidocaine which also produces a nonparallel shift to the right in the ACT 
curve (43). Propranolol, on the other hand, produces a small, parallel rightward 
shift in the ACT curve, indicating that propranolol decreases the conduction of both 
late and early extrasystoles: Practolol had no effect on the ACT curve, indicating 
that the effect of propranolol and pranolium on this relationship was not due to 
beta-adrenergic receptor blockade. 
Interestingly, Dresel and Potter found that neither propranolol (2 mg/kg) nor 
practolol (0.5-4 mg/kg) affected impulse conduction in either atrial or ventricular 
muscle. Pranolium, however, produced a dose-related decrease in both atrial con- 
duction (as measured by the increase in time from the pacing stimulus artifact to 
the atrial electrogram on a His bundle recording) and ventricular conduction (as 
measured by the increase in time from the His bundle depolarization to the ven- 
tricular electrogram) . 
That the actions of pranolium on conduction are not related to a local anesthetic 
action of this drug has been shown by Schuster et al. (71). These workers have 
studied the comparative effects of M of both pranolium and propranolol on 
intact and desheathed frog sciatic nerve (Fig. 6). Note that while propranolol pro- 
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FIG. 5. Transmembrane potential recordings from canine Purkinje fiber paced at 1500 msec 
cycle length. Top trace at fast sweep speed shows minimal interval for propagated response 
(effective refractory period) is 230 msec in the control state. Lower left trace was photographed 
at slow sweep speed and shows the response to pacing at a 1500 msec cycle length 60 min 
after administration of pranolium. Lower right trace shows that effective refractory period is 
increased to 1010 msec. 
produced no change in the spike potential in either intact or desheathed nerves. So, 
while pranolium clearly alters conduction and refractoriness in canine myocardial 
tissue, these effects are not related to any local anesthetic properties of the drug. 
Additionally, the in vitro electrophysiological properties of pranolium occur despite 
the absence of beta-adrenergic receptor blocking action. 
ZN VZVO ELECTROPHYSIOLOGY 
The results of in viva studies with pranolium are consistent with the drug’s in 
vitro actions. In the initial work of Kniffen et al. (35),  pranolium produced a dose- 
related prolongation of ventricular ERP and AV nodal functional refractory period 
(AVFRP) and an increase in AV conduction time. Figure 7 and Table 1 summarize 
the data demonstrating the ability of pranolium to increase ventricular refractoriness 
in the anesthetized dog. Pranolium elevates the ventricular ERP at 5 and 10 mgkg 
and shifts the ventricular strength-interval curve progressively to the right without 
altering diastolic excitability. A similar effect of pranolium on refractoriness is seen 
on the AV node (Tables 2 and 3). Pranolium, 2-8 mgkg, progressively increases 
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FIG. 6. The effects of propranolol, M, and pranolium (UM-272). M, upon spike 
amplitude in the frog sciatic trunk. Experiments with propranolol were performed on intact nerves 
and pranolium was tested in both the intact and desheathed nerve preparations. Results are 
plotted as the percentage decrease in the overall amplitude of the nerve spike potential. Unlike 
propranolol, pranolium did not cause a significant decrease in spike amplitude over the course 
of 1 hr in either preparation. Pranolium is devoid of local anesthetic activity. (From Schuster et 
at., ref. 71, with permission.) 
the AVFRP and this results in a decrease in the maximum following rate of the 
AV node to atrial pacing. While in the control state, the maximum pacing rate was 
291.9 ? 6.5 (mean & SEM) beatdmin; after 8 mg/kg this maximum rate decreased 
to 212.2 ? 3.1 beatdmin, a decrease of 39%. Note that there is good agreement 
between the increase in AVFRP calculated from the maximum driving rate in Table 
3 and the actual increase in AVFRP determined by the atrial premature systole 
technique (Table 2 ) .  Pranolium at 8 mg/kg was also found to significantly increase 
AV conduction time from a control value of 146.8 * 5.2 msec to a maximum 
value of 245.0 ? 5.0 msec. 
When studying the actions of pranolium on automaticity, Kniffen et al. (35) 
found pranolium to decrease both spontaneous SA nodal and atrial and ventricular 
automatic activity. In 5 dogs in which the SA node had been crushed, 3 mg/kg of 
pranolium lowered the AV junctional rate from 76.2 & 11.6 beatshin to 50.8 * 6.3 
beats/min and a second dose of 3 mg/kg further reduced the rate to 37.0 3~ 5.2 
beatdmin. AV junctional escape time, defined as the interval between the last 
electrically driven beat and the first nondriven QRS complex, was also prolonged, 
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FIG. 7. Effect of pranolium on' the canine ventricular strength-interval curve. The abscissa 
shows the time interval between the last paced beat and the premature test impulse. The ordinate 
expresses the strength of the test impulse in milliamperes. This example shows that increasing 
doses of pranolium successively shift the ventricular strength-interval curve to the right by 
increasing the effective refractory period without changing the diastolic threshold to excitation. 
(From Kniffen et al., ref. 35, with permission.) 
TABLE 1 .  Effect of pranolium on the ventricular 
strength-interval curve 
Effective refractory period (msec) 
After pranolium at mg/kg, i.v. 
Exp. No. Control 1 .o 5.0 10.0 
1 107 110 115 125 
2 110 115 125 140 
3 125 135 145 150 
4 115 110 125 135 
5 1 25 140 145 160 
M ? SE 116.4 t 3.7 122.0 2 6.4 131.0 -t 6.0' 142.0 t 6.0b 
' p  < .005. 
bp < .001. 
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TABLE 2. Effect of pranolium on the A V functional refractory period and conduction 
time studied by the atrial premature systole technique (N = 5) 
AV Conduction AV Functional refractory period 
Time (msec) % Change p Value Time (msec) % Change p Value 
Control 146.8 ? 5.28 210.8 f 10.96 
Pranolium, i.v. 
2.0 mg/kg 175.6 2 6.43 19.6 <.007 241.2 5 13.24 14.4 c.005 
4.0 mglkg 190.6 f 7.87 29.8 c.001 250.4 ? 12.09 18.8 c.001 
8.0 rnglkg 245.0 f 5.00 43.8 C.001 275.7 a 18.20 30.8 c.010 
TABLE 3. Effects of pranolium on the functional refractory period as 
determined from the maximum A V transmission rate (N = 5) 
Functional refractory period 
Max. rate of AV 
transmission Calculated 
(beatshin ? time ? SE 
Drug SE) (msec) % Change p Value 
Control 291.9 2 6.5 205.9 f 4.8 
Pranolium, i.v. 
2.0 rngikg 253.2 t 9.0 238.2 2 8.8 15.7 C.05 
4.0 mg/kg 235.7 t 10.4 256.4 ? 10.8 24.5 C.005 
8.0 mglkg 212.2 -t 13.1 286.8 ? 16.3 39.3 C.005 
from a control value of 2.9 ? 1.5 to 6.9 & 2.2 ( p  < .05) sec after the first dose 
of 3 mg/kg and to 12.6 & 3.4 ( p  < .05) sec after the second dose of 3 mg/kg of 
pranolium. In dogs in which a suture was placed through AV junctional tissue near 
the bundle of His, both atrial and ventricular rate could be studied independently. 
Each of two doses of 3 mg/kg of pranolium effectively reduced both atrial and 
ventricular rate, confirming the in vitro work and demonstrating that pranolium 
decreases automaticity in the SA node, atria, as well as ventricular myocardium. 
More recently, pranolium has been shown to alter refractoriness and conduction 
in ischemic myocardium. Gibson et al. (15) studied the effect of the drug on the 
ERP and on ventricular activation times (AT) in both normal and acutely ischemic 
myocardium in the anesthetized dog. Ischemia was produced by occlusion of se- 
lected diagonal branches of the left anterior descending coronary artery (LAD), and 
stainless steel bipolar electrodes were placed in the area previously perfused by the 
occluded vessel (IZ) and in the area perfused by the nonoccluded left circumflex 
artery (NZ). Table 4 presents the data showing the effects of two different doses 
of pranolium as compared with saline-treated controls (see legend for dose). In 
saline-treated dogs, occlusion of an LAD diagonal branch produced an immediate 
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TABLE 4. Effect of pranolium on fhe effective refractory periods of ischemic and nonischemic 
myocardium 
Group A Group 6 Group C 
Min (9) (5) (7) 
after 
occlusions NZ (rnsec) IZ (msec) NZ (msec) IZ (rnsec) NZ (msec) IZ (msec) . 
0 I46 t 4.9 143 f 3.9 168 f 2.9 164 t 1.7 201 t 15.6 209 f 7.5 
10 147 t 5.0 130 k 3.gbgC 169 f 2.4 179 f 6.7b3c 196 t 13.5 243 5 11.lC 
30 149 -t- 4.6 120 f 3.oblc 166 ? 2.8 165 t 4.9 192 f 14.5 219 f 6.gb 
40 148 Ifr 4.3 120 5 3.8b,c 166 f 2.8 161 f 5.2 190 t 13.4 219 t 7.1b 
50 149 t 5.0 120 f 5.4b9c 164 t 3.8 153 f 5.6 188 f 13.4 216 f 6.5b 
60 149 t 5.2 118 t 6.4b*c 163 f 4.6 156 Ifr 5.8 187 t 13.8 216 +- 6.gb 
80 148 t 5.3 120 t 7.0b*c 163 f 4.7 158 t 5.7 190 t 14.1 208 t 9.1 
100 147 t 5.2 120 f 7.ObvC 163 t 3 . 2  163 f 3.2 188 t 14.3 208 f 8.5 
120 146 t 5.8 126 f 6.7b9c 162 I 3.8 166 f 2.9 185 f 13.4 211 f 8.5 
20 148 f 4.8 124 t 2.7b.c 168 I 3.0 177 t 7.2 198 14.5 224 t 6.3b 
NZ, nonischemic myocardium; IZ, ischemic myocardium; group A, saline treatment; group 6. pran 
olium, 5 mg/kg bolus and 25 pglkglmin infusion; group C, pranolium, 10 rnglkg bolus and 50 pg/kg/mir 
infusion. Numbers in parentheses are numbers of experiments. 
'Thirty minutes post-treatment. 
bp < .05; IZ, 0 rnin compared to test. 
c p  < .05; IZ compared to NZ. 
decrease in IZ ERP while no changes occurred in the NZ. In contrast, after pran- 
olium, control ERP was considerably prolonged, and after occlusion the IZ ERP 
was either greater than or the same as the NZ ERP, indicating that pranolium had 
decreased the disparity in refractoriness between the normal and the ischemic my- 
ocardial regions. Additionally, pranolium increased ventricular AT prior to occlu- 
sion and both doses of pranolium significantly elevated AT in the IZ after occlusion 
(Table 5 ) ,  indicating that pranolium was preferentially slowing myocardial con- 
duction in the IZ. 
Patterson and Lucchesi (62) made similar observations in the chronically is- 
chemic, conscious dog subject to programmed electrical stimulation. Figure 8 de- 
picts the effect of pranolium (5 or 10 mg/kg) after chronic administration for 2 days 
(days 3 and 4) followed by withdrawal of the drug on day 5. Dogs had previously 
undergone experimentally induced myocardial infarction by a 90-min occlusion of 
the LAD followed by reperfusion through a critical stenosis. When the values on 
days 3 and 4 are compared with those on day 5 (drug withdrawal), pranolium 
produced considerable prolongation of the ERP and an increase in IZ and NZ Q- 
EG-interval (defined as the interval between the Q wave of the lead I1 ECG and 
the major deflection of the bipolar electrogram, a measure of conduction). These 
increases in conduction time and refractoriness were associated with a decrease in 
the severity of the arrhythmic response of pranolium-treated dogs to programmed 
electrical stimulation as compared with nontreated controls. 
To summarize, pranolium, both in v i m  and in vivo increases conduction time 
as a result of its ability to decrease the V,,, of the AP. In addition, pranolium 
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TABLE 5. Effect of pranofium on activation time in ischemic 
and nonischemic myocardium 
Group A 
( 61 
Group B Group C 
(5) (6) . .  . .  . .  
Min 
after NZ 
occlusion NZa (msec) I2 (rnsec) (msec) IZ (msec) NZ (msec) IZ (msec) 
0 - 1 e 1 . 0  - 1 t 0 . 6  5 2 1 . 4  3 t 1 . 1  1 4 t 2 . 4  6 t 1 . 8  
10 0 t 1.1 -9 f 3.4b 7 I 2.1 16 t 5.gb 14 t 2.5 19 f 11.0 
20 - 2  * 1.2 4 rt 3.5 6 2 1.9 13 t 4.4b 12 t 3.5 16 t 8.8 
30 0 f 1.8 2 2 2.9 ,8 2 2.1 13 t 4.2b 14 t 3.6 18 f 7.2b 
40 - 2  f 1.2 6 t 3.7 9 t 2.7 14 f 3.!ib 13 t 3.0 14 t 3.3b 
50 -2  t 1.7 4 f 3.4 6 2 2.3 14 ? 3.5b 14 e 2.7 16 t 2.gb 
60 - 2  ? 2.1 3 t 3.6 4 ? 2.8 14 t 3.5b 13 t 2.7 14 t 2.ab 
80 -2  f 1.7 2 t 2.7 9 2.7 17 t 4.6b 13 f 2.3 16 t 4.3b 
100 -1  t 2.0 3 t 3.6 8 2 3.0 15 t 3.2b 13 t 2.1 19 t 4.ab 
120 -1.5 t 2.0 5 t 3.3 7 t 3.1 15 f 3.1b 13 f 2.6 17 rt 2.gb 
NZ, nonischemic myocardium; IZ, ischemic myocardium; group A, saline treated; group B, 
pranolium, 5 mglkg bolus and 25 pg/kg/min infusion; group C, pranolium, 10 mg/kg bolus and 50 
pglkglmin infusion. Numbers in parentheses indicate number of experiments. 
aData are expressed as change in activation time, i.e., test-control (pretreatment). 
Wgnificant differences from 0 min values are: p < .05. 
decreases automaticity in the SA nodal tissue, the AV junction, and the ventricle. 
This action is a result of pranolium’s ability to decrease the slope of spontaneous 
phase 4 depolarization. Finally, pranolium increases the ERP in both the atrio- 
ventricular conducting system and the canine ventricle. The relationship between 
these electrophysiologic actions and the antiarrhythmic actions of pranolium will 
be discussed in the following sections. 
ANTIARRHYTHMIC ACTIVITY 
Pranolium possesses antidysrhythmic properties in a number of experimental 
models of ventricular arrhythmias. 
Ouabain-Induced Ventricular Tachyarrhythmias 
One of the most widely used animal models for the determination of antiar- 
rhythmic activity is that of the production of ventricular tachycardia in anesthetized 
dogs by the administration of ouabain (41). The criteria used to determine antiar- 
rhythmic activity are: (a) reversion to normal sinus rhythm for a specified period 
of time, usually not less than 30 min; and (b) the failure of right vagal stimulation 
to expose automatic ectopic ventricular activity during sinus node arrest. 
In a series of experiments performed in our laboratory, Schuster et al. (71) 
reported pranolium, given intravenously to dogs with ouabain-induced ventricular 
tachycardia, was successful in reestablishing normal sinus rhythm in doses of 2-3 
mg/kg. Also, Patterson et al. (59), in a second series of experiments, found that 
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FIG. 8. Myocardial activation times and 
effective refractory periods. Myocardial ac- 
, tivation times (Q-EG intervals) were mea- 
sured for normal (NZ) and ischemic (IZ) 
myocardium both during (days 3 and 4) and 
afler (day 5) chronic pranolium administra- 
tion. Effective refractory periods (ERP) in 
?& pq0.05 normal myocardium were also measured. 
Data are expressed as means f SD 
( N  = 8). Pranolium administration in- 
creased myocardial activation times in both 
normal and ischemic myocardium 
(p < 0.05). Pranolium administration also 
produced an increase in ventricular refrac- 
toriness (p < 0.05). (From Patterson and 
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pranolium, when given orally in doses of 40 and 60 mgkg to anesthetized dogs 
with ouabain-induced ventricular tachycardias, reestablished normal sinus rhythm 
within 64 & 7 and 25 ? 9 min, respectively, after oral administration (Fig. 9). 
Despite the ability of pranolium to slow conduction in ventricular myocardium 
and to increase refractoriness in AV nodal tissue, it appears to be an ideal drug for 
the treatment of arrhythmias resulting from digitalis toxicity. Thus, pranolium can 
be given safely in the presence of the digitalis glycosides, and concurrent admin- 
istration of digitalis glycosides does not appear to be detrimental as far as impeding 
atrioventricular transmission. 
Effects of Pranolium on Ventricular Automaticity After Experimentally 
Induced Myocardial Infarction 
Another method of determining the antiarrhythmic efficacy of a drug is by ad- 
ministering the agent to a conscious dog prepared by the method of Harris (21). 
Schuster et al. (71) reported that in dogs studied 48 hr after a two-step ligation of 
LAD, each animal exhibited spontaneous ventricular arrhythmias in which an av- 
erageof76.3%ofthetotalnumberofheartbeats(102.7 ? 13.9outof 135.1 ? 9.9 
beatdmin) originated from ventricular foci. Pranolium, in an average dose of 5.7 
mg/kg (2.5-10 mgkg) significantly reduced the ectopic heart rate to 16.0 5 10.7 
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FIG. 11. The effect of pranolium in 7 conscious dogs 48 hr after experimentally induced 
myocardial infarction. Each animal was studied during the phase of spontaneous ventricular 
tachycardia and received an intravenous infusion of pranolium until sinus rhythm was restored. 
Ectopic beats were defined as those beats not of sinoatrial origin. (From Schuster el at., ref. 
71, with permission.) 
of pranolium persisted in 6 of 7 animals for at least 1 hr. In 2 animals, the 
electrocardiogram was monitored for 2 hr with no significant increase in ectopic 
rate observed. 
Although ouabain-induced ventricular arrhythmias and ventricular tachyarrhyth- 
mias present 24-72 hr after experimental myocardial infarction are commonly used 
to evaluate antiarrhythmic drugs, these models poorly simulate the basis for ven- 
tricular arrhythmias in man. Both cardiac glycoside-induced ventricular arrhythmias 
and ventricular arrhythmias present 24-72 hr after myocardial infarction result from 
altered Purkinje fiber automaticity (24,371. Enhanced automaticity of damaged 
myocardial tissue may play a role in some arrhythmias. However, it has been 
suggested that most ventricular arrhythmias associated with myocardial ischemia 
and infarction in man probably result from localized reentry of myocardial electrical 
activity (10,24,37). Accurate evaluation of antiarrhythmic activity of drugs requires 
animal models that more closely simulate the clinical situation in man. 
The presence of reentrant ventricular arrhythmias, particularly complex ventric- 
ular arrhythmias such a.s multiform premature ventricular beats, coupled extrasys- 
toles, and ventricular tachycardia (Lown grades 3-5), in patients with coronary 
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artery disease is a major risk factor associated with the future development of 
ventricular fibrillation (68,72,80). Prevention of ventricular fibrillation appears to 
be associated with suppression of the continuous underlying myocardial electrical 
instability responsible for the development of ventricular tachyarrhythmias and 
ventricular fibrillation rather than with an overall reduction in the number of pre- 
mature ventricufar beats (26,50,5 1 ) .  Prevention of reentrant ventricular arrhythmias 
and ventricular fibrillation may be dependent upon the ability of the drug to affect 
the underlying substrate, the antifibrillatory properties of the drug, rather than upon 
the ability to suppress premature ventricular beats, the antiarrhythmic properties of 
the drug. Therefore, the following animal models were used to evaluate the anti- 
fibrillatory properties of pranolium. 
Reentrant Ventricular Arrhythmias Resulting from Acute 
Coronary Artery Occlusion 
Schuster et al. (71) studied the ability of pranolium to prevent the development 
of ventricular fibrillation resulting from repeated occlusions of the LAD coronary 
artery in the anesthetized dog. Each occlusion lasted 10 min and was followed by 
reperfusion. In control animals, 1 1 of 15 animals fibrillated after one, two, or three 
occlusions. In the pranolium-treated group (10 mg/kg, iv . ) ,  only 5 of 15 animals 
developed ventricular fibrillation ( p  < 0.025) (71). 
In a second series of experiments in which occlusion of the anterior descending 
coronary artery was maintained for 20 min, 10 out of 10 untreated animals developed 
ventricular fibrillation upon occlusion or upon reperfusion. In the pranolium-treated 
group, none of the animals fibrillated during the occlusion and 4 of 10 fibrillated 
upon restoration of coronary artery blood flow. The difference between control and 
drug-treated groups proved significant ( p  < 0.05) (71). 
Ventricular Fibrillation Threshold Determination 
In unpublished experiments from our laboratory, Kniffen (32) showed that pran- 
olium was effective in elevating the ventricular fibrillation threshold (the lowest 
current intensity producing sustained ventricular fibrillation) in the anesthetized 
dog. In these experiments the sinus node was crushed and the ventricular rate 
maintained by electrical pacing at a frequency of 2 Hz. A train of 60-Hz pulses 
(350 msec in duration) was synchronized to the ventricular pacing stimulus and 
was delivered after every sixth driven beat. 
Control measurements of fibrillation threshold were 5.4 k 0.38 mA (X Ifi SEM). 
After a temporary 2-min occlusion of a branch of the anterior descending coronary 
artery, the fibrillation threshold was reduced to 2.4 2 0.2 mA. Administration of 
pranolium (5 mglkg) increased the control values to 11.5 +- 1.9 mA at 30 min 
after drug (p < 0.01). As seen in Fig. 12, pranolium administration also signifi- 
cantly increased ventricular fibrillation thresholds determined in the presence of 
regional myocardial ischemia (6.7 ? 0.18 mA versus 2.4 & 0.2 mA predrug) 
( p  < 0.05). 
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FIG. 12. Ventricular fibrillation threshold deter- 
minations. Gated trains (60 Hz, 350 msec train 
duration) of 4-msec pulses were introduced into 
the right ventricle. Pranolium (5 mg/kg) signifi- 
cantly increased the current intensity needed to 
produce ventricular fibrillation. (From Kniffen, ref. 
32, with permission.) 
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Reentrant Ventricular Arrhythmias Produced by Programmed Electrical 
Stimulation in Conscious and Anesthetized Dogs 
Recently, the technique of programmed electrical stimulation (PES) has been 
used to expose the underlying myocardial substrate responsible for recurrent ven- 
tricular tachyarrhythmias (including ventricular fibrillation) in patients exhibiting 
these arrhythmias spontaneously (27-29,79). Exposure of the arrhythmia with this 
technique (involving the transvenous or transarterial placement of electrocatheters 
in either right or left ventricle followed by insertion of 1, 2, or 3 premature ven- 
tricular beats during atrial or ventricular pacing) allows the serial testing of a number 
of antiarrhythmic drugs to determine which dose of which particular agent best 
suppresses the arrhythmia. This technique has also lent itself to the examination of 
antiarrhythmic agents in the experimental animal (17,46,58,60,62,63). Gibson and 
Lucchesi (17) examined the effect of pranolium in anesthetized dogs which had 
previously undergone experimentally induced myocardial infarction. The dogs were 
instrumented with a bipolar plunge electrode inserted into the septum, an atrial 
pacing electrode, and bipolar composite electrodes in which one composite electrode 
was placed over the ischemic injured myocardium and the other electrode placed 
over adjacent normal ventricular myocardium (Fig. 13). Before pranolium admin- 
istration, premature ventricular stimuli delivered to the bipolar septa1 electrode 
elicited nonsustained ventricular tachycardia in 3 animals, sustained ventricular 
tachycardia in 2 animals, and ventricular fibrillation in 3 animals. In each animal, 
these arrhythmias were associated with depressed, delayed cardiac conduction through 
injured myocardium. The injured zone electrocardiogram recorded from the bipolar 
composite electrode fractionated into a continuous series of asynchronous spikes 
which bridged the entire diastolic interval between consecutive beats (Figs. 14 and 
15). Thirty minutes after intravenous pranolium (5 mg/kg), PES produced nonsus- 
tained ventricular tachycardia in 2 animals. Ventricular arrhythmias were not in- 




FIG. 13. Instrumentation for programmed electrical stimulation. A bipolar electrode was sewn 
to the left atrial appendage to enable control of ventricular rate via atrial pacing. A plunge bipolar 
electrode was placed into the interventricular septum adjacent to the right ventricular outflow 
tract. Composite bipolar electrodes were placed on normal and ischemically injured left ven- 
tricular myocardium. 
pranolium (345 2 5 msec) was significantly increased compared with predrug 
values (187 rt 16 msec) (p < 0.05). The antiarrhythmic action of pranolium was 
maintained in excess of 2 hr after intravenous dosing. 
In each experiment, pranolium progressively depressed the amplitude and du- 
ration of the ischemic fragmented deflection recorded from the injured zone elec- 
trogram during the ventricular beats, although having no effect on the discrete 
potentials recorded from the adjacent normal zone. Before pranolium, the injured- 
zone potentials persisted for 169 5 18 msec and thus bridged the diastolic interval. 
The duration of the diastolic electrical potentials was reduced to 110 k 22 msec 
(p < 0.05) 30 min after pranolium (17). This action probably results from the 
ability of pranolium to slow conduction preferentially in injured myocardium, an 
action previously demonstrated in acutely ischemic ventricular myocardium (1 5). 
Conduction in the most severely depressed and delayed areas may be further de- 
pressed by pranolium so that conduction block occurs in the injured myocardium. 
This is supported by the observation that the cycle length of the tachycardia increased 
after pranolium. This suggests that impairment of already depressed cardiac con- 
duction and prolonged refractoriness of different segments of a reentrant pathway 
are involved in the antiarrhythmic actions of pranolium and that these electrophys- 
iologic effects may result in an antifibrillatory action. 
Chronic Administration of Pranolium in the Conscious Dog 
Patterson and Lucchesi (62) examined the actions of pranolium in conscious dogs 
that had previously been subjected to myocardial infarction and instrumented as 
described previously, and then subjected to PES beginning 3 days post-myocardial 
infarction. 
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FIG. 14. Initiation and termination of sustained ventricular tachycardia by premature stimuli. 
NZ, composite electrograni from normal myocardium; IZ, composite electrogram from injured 
myocardium; L-2, lead II ECG. In panel A, a premature beat (arrowhead) produced ventricular 
tachycardia. Panel B, uniform ventricular tachycardia is seen. The epicardial activity of the 
injured zone (middle trace) is fragmented and asynchronous, whereas that of the normal zone 
(upper trace) remains synchronous and discrete. Panel C,  a burst of ventricular pacing (arrow- 
head) is used to terminate the tachycardia. (From Gibson and Lucchesi, ref. 17, with permission.) 
Pranolium (5 or 10 mg/kg) was administered intravenously every 12 hr beginning 
24 hr before PES on day 3 and continued through 12 hr prior to PES on day 4. 
PES was performed 12 hr after the last dose of pranolium on days 3 and 4, 30 min 
after acute pranolium administration on day 3, and 36 hr after the last dose of 
pranoliurn on day 5. Twenty dogs served as saline-treated controls and underwent 
PES on days 3 and 4 after myocardial infarction. 
The results of PES in saline- and pranoliurn-treated animals are shown in Fig. 
16. Ventricular tachyarrhythmias were induced by PES in all 20 control animals 
on days 3, 4,  and 5 after myocardial infarction. Sustained ventricular tachycardias 
had a cycle length of 186 2 31 msec. Self-terminating ventricular tachycardias 
(nonsustained ventricular tachycardia) were 18 ? 7 beats in duration with a cycle 
length of 169 2 13 msec. In pranolium-treated animals, PES performed 12 hr after 
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FIG. 16. Effect of pranolium (UM-272) on indu- 
cible ventricular reentrant arrhythmias in the con- 
scious dog. Note that the termination of pranolium 
treatment caused an exacerbation of arrhythmias 
in all dogs. NI, noninducible; VT,, nonsustained ven- 
tricular tachycardia; VT, sustained ventricular tach- 
ycardia; VF, ventricular fibrillation. The number of 
animals (n) is included in each ball. 
(cycle length, 296 and 316 msec) and sustained ventricular tachycardia in 2 animals 
(cycle length, 304 and 320 msec) on day 3. The duration of nonsustained ventricular 
tachycardia was 4.2 it 1.6 beats. If ventricular tachycardia could not be induced 
with PES at two times diastolic threshold ( N  = 4), PES at five times diastolic 
threshold was performed., resulting in nonsustained ventricular tachycardia (3.6 -t 1.2 
beats) in 2 animals. 
Thirty minutes after the acute administration of the third dose of pranolium on 
day 3, ventricular tachyarrhythmias could not be induced in 7 of 8 animals with 
PES at two or five times diastolic threshold. In the remaining animal, the cycle 
length of the sustained ventricular tachycardia had increased from 324 to 345 msec. 
On day 4 after myocardial infarction, PES in pranolium-treated animals at two 
times diastolic threshold failed to elicit ventricular tachycardia in 5 animals. Non- 
sustained ventricular tachycardia (cycle length, 284 and 3 12 msec) was produced 
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in 2 animals and sustained ventricular tachycardia (cycle length, 320 msec) in 1 
animal. PES at five times diastolic threshold produced nonsustained ventricular 
tachycardia in 1 of 5 noninducible animals. 
On day 5 after myocardial infarction, 36 hr after withdrawal of pranolium, PES 
produced ventricular fibrillation in 5 animals and sustained ventricular tachycardia 
in 3 dogs. The sustained ventricular tachycardias were rapid (132 L 19 msec cycle 
length) and degenerated to ventricular fibrillation in all 3 animals. 
Administration of pranolium raised the ventricular refractory period to 183 +- 12 
msec on day 3 and 191 +- 18 msec on day 4. The effective refractory period of 
the normal left ventricle on day 5, after withdrawal of pranolium, was 152 +- 5 
msec (p < 0.05 versus day 3 or day 4). An example of PES in a pranolium-treated 
animal on days 3-5 after myocardial infarction is shown in Fig. 17. This study 
demonstrates pranolium’s ability to inhibit inducible cardiac tachyarrhythmias. 
Conscious Canine Model of Sudden Coronary Death 
Animal models used to evaluate the antiarrhythmic efficacy on potential thera- 
peutic agents do not mimic the myocardial electrical instability and spontaneous 
occurrence of ventricular fibrillation associated with the development of sudden 
coronary death in man. The following canine model (61) of sudden coronary death 
has been developed recently in our laboratory and may provide a model that closely 
resembles the clinical situation in man in that ventricular fibrillation occurs spon- 
taneously in response to regional myocardial ischemia. 
Male mongrel dogs are anesthetized and myocardial ischemic injury is produced 
within the distribution of the left anterior descending coronary artery by temporary 
occlusion of the vessel (90 min) followed by reperfusion in the presence of a critical 
stenosis. The left circumflex coronary artery is isolated and the tip of a 30-gauge 
insulated silver wire is inserted into the vessel lumen (66). A plunge bipolar electrode 
is placed in the interventricular septum. Subcutaneous electrodes are implanted for 
electrocardiographic monitoring and the chest closed in layers. 
At day 3 after myocardial infarction, the animals were randomly assigned to 
treatment groups. The first group received saline and the second group received 
pranolium, 5 mg/kg i.v., every 6 hr. At 24 hr after initiation of drug therapy, PES 
was performed. The next drug dosage was administered and a current of 150 pA 
was applied to the intimal surface of the left circumflex coronary artery. A 9-volt 
battery, potentiometer, and biotelemetry transmitter were self-contained within the 
pouch of a nylon vest, thus allowing the animal free movement within a limited 
area. The lead I1 electrocardiogram was recorded continuously and stored on mag- 
netic tape. The current flow to the intimal surface of the LCX coronary artery was 
maintained for 12 hr. 
Administration of pranolium prevented the induction of ventricular tachycardia 
by PES. No sustained ventricular arrhythmias were produced in 9 animals while 
nonsustained ventricular tachycardia was produced in the 1 remaining animal. In 
control animals, PES produced nonsustained ventricular tachycardia in 7 animals, 
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FIG. 17. Prevention of reentrant ventricular arrhythmias by pranolium (UM-272). Normal zone 
(NZ) and ischemic zone ( I % )  bipolar composite electrograms, and a lead II ECG (11) are shown 
for serial studies on a representative pranolium-treated animal. Sinus cycle lengths (msec) are 
given in the lower left of each panel. A: Three days after myocardial infarction and during 
pranolium treatment (5 mg/kg every 12 hr), three premature ventricular stimuli with coupling 
intervals of 190, 180, and 180 msec failed to prdduce reentrant cardiac arrhythmias. B: The 
stimulus strength was raised to five times diastolic threshold, enabling shorter coupling intervals. 
Two premature ventricular stimuli at coupling intervals of 180 and 150 msec produced a slow 
three-beat tachycardia. Pranolium treatment was continued through day 4 after myocardial 
infarction (panels C and D). C: Three premature ventricular stimuli at coupling intervals of 200, 
180, and 180 msec failed to produce ventricular tachycardia. When an increase in stimulus 
strength to five times diastolic threshold enabled earlier coupling intervals to be obtained [180, 
160, and 160 msec (D)], three premature stimuli still failed to produce ventricular tachycardia. 
On day 5 after myocardial infarction, 36 hr after the last dose of pranolium three premature 
beats at two times diastolic threshold with coupling intervals of 160, 140, and 140 msec produced 
a polymorphic ventricular tachycardia which degenerated to ventricular fibrillation. (From Pat- 
terson and Lucchesi, ref. 62, with permission.) 
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sustained ventricular tachycardia in 2 animals, and no ventricular arrhythmias in 1 
animal. 
Current application to the intimal surface of the coronary artery produced de- 
nuding of the intimal surface and exposure of underlying collagen (66). Platelet 
aggregates and a platelet thrombus form, resulting in partial and, finally, complete 
occlusion of the vessel lumen. In saline-treated animals, ST-segment depression or 
elevation in excess of 0.3 mV developed at 99 ? 106 min (X t SD) after initiation 
of current flow to the intimal surface of the left circumflex coronary artery. Pre- 
mature ventricular contractions developed at 11 1 t 108 min followed by ventric- 
ular tachycardia at 131 t 118 min. Ventricular fibrillation developed in all 10 
saline-treated animals at 173 2 143 min. An example is shown in Fig. 18. 
Pranolium significantly reduced the incidence of ventricular fibrillation produced 
by acute myocardial ischemia within the left circumflex coronary arterial bed in 
the presence of left anterior descending myocardial infarction. Four of 10 animals 
survived for 24 hr after initiation of current flow to the intimal surface of the left 
circumflex coronary artery (p < 0.05). However, the drug did not prevent coronary 
artery thrombosis and myocardial ischemia. ST-segment changes appeared at 156 5 89 
min followed by the development of premature ventricular contractions at 168 t 93 
min. An example of a pranolium-treated animal is shown in Fig. 19. Survival curves 
for saline- and pranolium-treated animals are shown in Fig. 20. 
No differences were seen in myocardial infarct masses in the left anterior de- 
scending coronary artery distribution of saline- (19 ? 9% of total left ventricular 
mass) and pranolium-treated groups (19 t 13% of total left ventricular mass). In 
pranolium-treated animals surviving for 24 hr ( N  = 4), myocardial infarction 
(17 k 10% of total left ventricular mass) was present also in the left circumflex 
coronary artery distribution. Only left anterior descending myocardial infarction 
was observed in animals developing ventricular fibrillation. No evidence of ischemic 
injury was observed in the myocardial distribution of the left circumflex bed due 
to the rapid development of ventricular fibrillation in response to regional ischemia 
in the region of the LCX coronary artery. Thrombus mass, within the left circumflex 
coronary artery, was not significantly different between saline- (8 ? 7 mg) and 
pranolium-treated (14 k 14 mg) groups. 
The beneficial action of pranolium in preventing the induction of reentrant ven- 
tricular tachyarrhythmias and reducing the frequency of spontaneous development 
of ventricular fibrillation may be a result of the drug’s ability to depress myocardial 
conduction or increase myocardial refractoriness. As seen in the studies conducted 
in the anesthetized dog, pranolium depressed conduction in ischemically injured 
tissue to the extent that conduction failed where it was most severely depressed. 
Failure to conduct in these depressed regions resulted in failure of the premature 
beats to initiate reentrant arrhythmias (17). 
The increase in the refractory period of normal myocardium observed after chronic 
pranolium treatment in the conscious dog (62) is similar in magnitude to that 
observed with bretylium and other class I11 antiarrhythmic drugs. Augmentation of 
refractoriness in normal myocardium may prevent the induction of ventricular tach- 
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FIG. 20. The effect of pranolium (UM-272) upon survival in a canine model of sudden coronary 
death. Pranolium significantly increased ( p  < 0.05) survival at 24 hr. 
yarrhythmias by preventing premature beats from occurring at cycle lengths suf- 
ficiently early to establish a reentrant pathway. Alternatively, fractionation and 
prolongation of electrical activity within the ischemically injured zone produced by 
premature stimuli may fail to excite surrounding normal myocardium when refrac- 
toriness of the tissue exceeds the duration of electrical activity within the ischem- 
ically injured zone. 
Antiarrhythmic Activity in Man 
A study by Reele et al. (65)  evaluated the actions of intravenous pranolium in 
patients with ventricular arrhythmias. Pranolium, 10 mg/kg, given over a period 
of 100 min, significantly reduced the number and complexity of ventricular ar- 
rhythmias. This action was obtained without significant hemodynamic or systemic 
toxicity. However, further studies will be needed to establish efficacy and safety 
of pranolium in man. 
HEMODYNAMICS 
Beta-Blockade 
The lack of significant beta-adrenergic receptor blocking activity by pranolium 
was demonstrated by Schuster et al. (71). In the isolated rabbit right atrial strip 
preparation (Fig. 21), the cumulative dose response to the chronotropic effects of 
isoproterenol was studied in the presence and absence of pranolium. At a concen- 
tration of M pranolium produced no significant shift in the isoproterenol 
concentration-response curve. However, at a concentration of M ,  pranolium 
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FIG. 21. Effects of pranolium (UM-272) on the chronotropic concentration-effect curves for 
isoproterenol upon isolated right atrial strips. The cumulative log-concentration-effect curves for 
isoproterenol were determined in three separate groups-a control group and two groups in 
which the isoproterenol concentration-effect curves were determined 60 min after the addition 
of 10-8 and M did pranolium cause a statistically significant shift 
to the right in the concentration-effect curve (p < .01). (From Schuster et al., ref. 71, with 
permission.) 
produced a statistically significant shift to the right. In addition, both the inotropic 
and chronotropic responses to increasing doses of isoproterenol were studied before 
and after pranolium in open-chest anesthetized dogs (Table 6 ) .  The increase in both 
force and rate seen in response to isoproterenol alone did not differ significantly 
from that seen after 0.5, 4, or 10 mg/kg of pranolium. When a separate group of 
dogs was studied after receiving 0.5 mg/kg propranolol, there was a prominent 
shift to the right of the dose-response relationship to isoproterenol. Thus, pranolium 
does not exhibit significant beta-adrenergic receptor blocking activity in the anes- 
thetized open-chest dog and only a minimal degree of beta-adrenergic receptor 
blockade at a high concentration in the isolated rabbit right atrial strip. 
The isolated calf tracheal muscle brought to submaximal contraction with acetyl- 
P-methylcholine shows prominent relaxation in the presence of beta-adrenergic 
M pranolium. Only at 
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TABLE 6. Effects of pranolium and propranolol upon isoproterenol-induced chronotropic 
and inotropic responses 
Mean increase in heart rate Mean increase in force 
Dose of 
isoproterenol Before After 
























Pranolium, 0.5 mg/kg (N = 5) 
3.6 t 0.8 4.2 t 1.4 >.05 7.4 f 1.3 7.2 f 1.8 
8.9 t 1.5 5.4 t 4.2 >.05 17.6 f 3.3 13.4 t 1.5 
16.0 & 3.1 13.0 f 3.5 >.05 30.4 t 4.5 31.0 f 4.5 
28.6 f 3.8 27.0 f 4.6 >.05 54.4 f 17.0 59.6 f 8.3 
46.0 t 4.4 41.0 f 6.2 >.05 84.0 t 12.5 94.2 t 7.3 
Propranolol, 0.5 mglkg (N = 5) 
4.4 f 1.9 0.0 f 0.0 <.lo 8.q t 1.4 0.0 t 0.0 
7.6 t 2.1 0.2 t 0.2 <.025 16.2 f 2.1 0.2 f 0.2 
12.4 f 2.9 2.6 t 0.9 c.025 38.0 t 5.9 1.9 f 0.4 
26.0 f 5.4 3.0 f 0.9 c.010 65.9 f 7.8 4.8 f 0.6 
59.2 2 21.4. 7.0 f 1.4 <.005 95.4 t 12.5 11.8 t 1.7 
23.8 t 10.7 23.4 f 3.2 
27.0 t 6.1 46.8 t 6.2 
47.8 f 8.5 88.2 t 11.4 
Pranolium, 4.0 mg/kg (N = 5) 
5.2 t 0.7 3.2 f 0.9 >.05 11.4 t 7.9 7.6 t 1.2 
9.2 t 1.9 5.2 t 1.3 >.05 27.2 f 3.6 19.2 t 3.3 
18.0 f 4.7 13.2 t 2.6 >.05 54.2 t 6.3 46.0 & 7.0 
32.8 f 4.7 24.2 t 5.4 >.05 91.6 f 13.9 86.0 t 10.9 
53.4 f 6.0 38.8 f 6.6 >.05 137.2 f 17.4 139.4 f 16.8 
Pranolium, 10 mg/kg (N = 5) 
7.8 t 1.6 6.6 -c 1.7 B.4 29.4 f 3.9 26.8 t 4.3 
14.4 f 2.0 15.6 t 3.8 >.5 52.8 t 6.2 62.4 f 7.4 
27.2 t 3.7 28.8 t 5.3 >.5 76.4 f 7.2 93.4 t 8.5 
44.6 C 7.6 45.6 t 8.2 >.5 88.0 f 8.7 123.6 t 11.9 





















Force and heart rate were measured as increase from control. The values are the means f 
SE obtained from 4 groups of 5 dogs each. Data analyzed by self-paired analysis. The drug was 
administered intravenously. 
agonists. The cumulative dose-response curve for the beta-adrenergic agonist iso- 
proterenol, in this system, in the presence of increasing concentrations of propranolol 
shows a parallel shift to the right, characteristic of competitive antagonism. Pran- 
o h m ,  in the same concentrations as propranolol (10-7-10-5 M) fails to shift the 
cumulative dose-response curve to the right, thus showing a lack of competitive 
antagonism to isoproterenol at the beta-adrenergic receptor (5) .  
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Heart Rate, Blood Pressure, and Cardiac Output 
Pranolium significantly reduces heart rate, cardiac output (871, and blood pressure 
in anesthetized dogs (57). A decrease in heart rate and cardiac output was seen 
with an increasing cumulative dose (1 to 3 mg/kg). Systolic pressure, however, did 
not exhibit the same dose-response relationship. Single 3-mg/kg doses of pranolium 
produced a significant decrease in heart rate and cardiac output but a significant 
change in systolic pressure was not seen. 
Other investigators showed a significant decrease in heart rate after 5 mg/kg 
pranolium in anesthetized, open-chest dogs. Cardiac output and mean blood pressure 
were not significantly altered (40). 
O2 Consumption 
Since mammalian myocardium relies largely on aerobic metabolism for its energy 
requirements, the oxygen supply and demand ratio is crucial. The two major ways 
to increase this ratio are to increase myocardial oxygenation and/or decrease my- 
ocardial oxygen demand (56). Since the oxygen content of blood is fairly constant, 
the best way to increase myocardial oxygenation is to increase coronary blood flow 
through dilation of the coronary arteries. In hearts with coronary artery disease, the 
ability to increase flow is severely limited (1 1). A possible therapeutic approach, 
then, is to decrease myocardial oxygen demand (45). 
Possible pharmacologic interventions include the use of beta-adrenergic receptor 
blocking agents, such as propranolol, to decrease myocardial oxygen requirements 
(74). The use of such beta-adrenergic receptor blocking drugs, however, may 
aggravate many cardiac disease states by removing essential sympathetic compen- 
sation (6,76), especially in the failed heart. 
Pranolium decreases myocardial oxygen consumption in both the open-chest (33) 
or closed-chest (57,87) anesthetized dog and in the isolated perfused heart in siru 
(33,82). Pranolium, 10 mg/kg, has been shown to decrease myocardial oxygen 
consumption in anesthetized, open-chest dogs (Fig. 22) with only minimal changes 
in cardiac force and heart rate (33). In the closed-chest anesthetized dog (57) 
pranolium decreases myocardial oxygen consumption by decreasing heart rate and 
force, which also results in a decrease in cardiac output and tension-time index. In 
isolated, blood perfused canine hearts (Fig. 23) with a constant afterload, controlled 
ventricular volume, and lack of sympathetic reflexes, pranolium produces negative 
inotropic and a negative chronotropic effect which are associated with the decrease 
in oxygen consumption. When heart rate in this preparation is returned to predrug 
levels, however, myocardial oxygen consumption also returns towards control, 
indicating that it is the decrease in rate that is primarily responsible for the decrease 
in MV02. 
In the isolated blood-perfused canine heart, with constant coronary blood flow 
(82), intracoronary infusion of pranolium produces a significant decrease in MVOz 
at 1.3,2.5, and 5.0 mg/min for 25 min, but not at 0.3 mglmin for 15 min. Infusions 














FIG. 22. The effect of pranolium 
(UM-272) on the myocardial oxy- 
gen consumption in anesthetized, 
open-chest dogs. Myocardial ox- 
ygen consumption, calculated and 
expressed as ml/min/l00 g of left 
ventricle is displayed on the ordi- 
nare; the time after drug adminis- 
tration is displayed on the abscissa. 
Each bar represents the mean my- 
ocardial oxygen consumption 5 
SE of five separate experiments. 
Mean control 0, consumption in 
these experiments was 11.7 i 1.9. 
This was significantly reduced to 
7.3 1.1 at 10 min after drug and 
7.4 5 1.0 at 20 min after prano- 
lium. Even though the calculated 
myocardial oxygen consumptions 
were not significantly different at 
40 and 60 min after drug admin- 
- 
I 
MlNlJTES AFTER UM - 272 istration, the values were still be- 
low initial control values. (From 
Kniffen et al., ref. 33, with permis- 10 mg/kg 
sion.) 
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FIG. 23. The effect of pranolium 
(UM-272) on the myocardial oxy- 
gen consumption in isolated, blood- 
perfused canine hearts. Myocar- 
dial oxygen consumption, calcu- 
lated and expressed as ml/min/lOO 
g of heart, is displayed on the or- 
dinate; the time after drug admin- 
istration is displayed on the 
abscissa. Each bar represents the 
mean myocardial oxygen con- 
sumption * SE of five separate 
experiments. Mean control oxygen 
consumption in this study was 
3.1 5 0.2. This was significantly 
reduced to 2.1 t 0.1 at 20 min and 
2.2 2 0.2 at 40 min after drug. Even 
though the calculated myocardial 
oxygen consumption was not sig- 
nificantly different at 60 min, the 
value was still below initial control 
measurements. (From Kniffen et 
al., ref. 33, with permission.) 
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contractile force, myocardial oxygen consumption, and the epilendo coronary blood 
flow ratio. Coronary artery perfusion pressure increased significantly. Similar changes 
were seen 15 min after propranolol(O.5 mg/kg, i.v.) was administered to the donor 
dog (Fig. 24). In this isolated blood-perfused heart preparation with spontaneous 
heart rate, the intracoronary administration of pranolium (0.5 mg/min) produced 
significant stepwise decreases in heart rate and myocardial oxygen demands. At 
30, 60, and 120 rnin after the start of the infusion a stepwise increase in suben- 
docardial blood flow was similarly seen. The above changes were greatest at 30 
min after the start of infusion. In contrast, when the heart rate was held constant 
HR 120 




































































































































0.5 q / k g  
c 
I 
FIG. 24. Effects of pranolium (DMP) on propranolol on myocardial hemodynamics and oxygen 
consumption. Similar changes in heart rate (HR), contractile force (CFJ, coronary artery perfusion 
pressure (CAPP), left ventricular epicardial-endocardial blood flow ratio (EPVENDO) and my- 
ocardial oxygen consumption (MVOJ were observed after intracoronary infusions of pranolium 
for 15 rnin (N = 7) or 15 min after intravenous administration of propranolol (N = 6). Coronary 
blood flow (CBF) was held constant in both groups. Points and shaded areas represent 
mean +- SEM, respectively. 'Significant difference ( p  < .05) from preceding control value by 
paired comparison. (From Warltier et at., ref. 82, with permission.) 
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at 150 beats/min by right atrial pacing, the increase in subendocardial perfusion 
(epi/endo ratio) and the decrease in myocardial oxygen extraction were not as marked 
as in unpaced hearts. 
A significant increase in subendocardial perfusion and a significant decrease in 
MVOz were seen after 30 min of infusion, but the values returned toward control 
values at 60 and 120 min. The increase in subendocardial perfusion can be attributed 
primarily to the negative inotropic effect of pranolium, which results in an increased 
diastolic duration and perfusion time. Propranolol has been shown to produce similar 
increases in subendocardial perfusion as indicated by a decrease in epilendo ratio 
(920). 
Gross et al. (19) showed that pranolium (1,5, and 10 mg/kg, i.v.) produced a 
small stepwise increase in the endolepi ratio of the nonischemic myocardium and 
a larger increase in the ischemic myocardium. Propranolol had a similar effect in 
nonischemic and ischeniic regions of the left ventricle, but pranolium produced 
more favorable effects on ischemic subendocardial blood flow. 
Both propranolol and pranolium have a negative inotropic effect and limit the 
severity of epicardial ST-segment elevations after experimental coronary artery 
occlusion (34). In these experiments, when hearts were paced back to their control 
levels, propranolol failed to prevent the ST-segment changes. Pranolium, however, 
reduced the extent of ST-segment changes even when the hearts were paced back 
to their control state. 
Regional Myocardial Ischemia 
Several investigators have successfully used pharmacologic interventions to re- 
duce the amount of cardiac tissue susceptible to damage from myocardial ischemia 
(23,34,40,44,45). Pranolium has been shown to be beneficial in reducing infarct 
size due to experimental coronary artery occlusion (36,40) in anesthetized open- 
chest dogs. Lucchesi et al. (40) examined the effect of pranolium in reducing infarct 
size and electrocardiographic changes resulting from a 60-min occlusion of the left 
circumflex coronary artery followed by reperfusion. All control animals showed 
evidence of myocardial ischemia due to coronary artery occlusion as evidenced by 
ST-segment elevations in a lead I1 ECG, ventricular premature beats, and ventricular 
tachycardia. Progressive increases in Q-wave amplitude and loss of R-wave am- 
plitude were seen in all control animals after release of the occlusion (Fig. 25). In 
pranolium-treated dogs (5  mg/kg, 30 min before occlusion and 2.5 mg/kg every 
90 min for a total dose of 15 mg/kg) neither an elevation in the ST-segment nor a 
loss of R-wave amplitude was observed (Fig. 26).Upon reperfusion, pathologic Q- 
wave formation was not evident in the treated group. Ectopic beats were significantly 
reduced in pranolium-treated dogs (15 mg/kg) compared with control animals sub- 
jected to LCX occlusion during the first 4 hr of reperfusion. A dose of 12.5 mg/kg 
similarly reduced ectopic beats, but the effect was not as marked within the hour 
as with the higher dose At 24 hr after reperfusion, fewer premature ventricular 
contractions were seen in pranolium-treated dogs, indicating that many more of the 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The technique of tetracycline deposition surrounding the infarcted tissue (25,42,77) 
was employed to delineate infarcted tissue from noninfarcted tissue. UV examination 
shows that tetracycline is deposited primarily in the periinfarct tissue forming a 
fluorescent ring around nonfluorescent or infarcted myocardium. The central portion 
of the infarct does not show a positive tetracycline stain because of the lack of 
perfusion to this area. The rim of positive tetracycline stain (fluorescent under UV 
light) represents that portion of the infarct that has been irreversibly injured due to 
an ischemic event, but is still being perfused. This area represents viable myocar- 
dium that may be salvaged using proper pharmacologic approaches. 
NBT (nitroblue tetrazolium), on the other hand, is reduced by dehydrogenase 
activity in both normal myocardium and the relatively ischemic tissue delineated 
by tetracycline fluorescence under UV light. These two areas are stained a deep 
blue, thus allowing delineation of viable and infarcted tissue. 
In pranolium-pretreated hearts examination of tetracycline-stained hearts under 
UV light showed a “patchy” or “nonconfluent” distribution of fluorescent material 
in the myocardium supplied by the LCX in all but two hearts. The confinement of 
the fluorescent material to the endocardial region was noted in all but two hearts, 
and in these hearts the fluorescent material extended to the midmyocardial zone. 
The NBT stain showed nonstaining areas of myocardium confined to the endocardial 
zone. 
Infarct size determination by gravimetric analysis showed a significant dose- 
related reduction in the extent of myocardial insult in pranolium-treated animals. 
The results show that pranolium treatment can significantly reduce the amount of 
myocardium that undergoes necrosis as a result of a temporary occlusion of the 
circumflex coronary artery and, in contrast to propranolol, does not produce beta- 
adrenergic receptor blockade which could compromise cardiac function. 
Electrocardiographic changes such as epicardial ST-segment elevations, loss of 
R-wave amplitude, the development of pathologic Q-waves, and biochemical changes 
such as the loss of myocardial creatine kinase (CPR) activity have been used to 
determine and/or predict the extent of myocardial ischemic injury as a result of 
coronary artery occlusion (14,18,23,31,45,52). Ku and Lucchesi (36) used these 
parameters along with gravimetric determination of infarct size to assess the effect 
of pranolium pretreatment in protecting the ischemic heart against irreversible dam- 
age. 
Dogs were randomized to saline control and pranolium (2 mg/kg given 30 min 
before LAD occlusion then 2 mg/kg every 90 min for a total intravenous dose of 
10 mg/kg) treatment groups. After 90 minutes of LAD occlusion in anesthetized, 
open-chest dogs, coronary flow was reinstituted gradually so as to reduce the 
incidence of hemorrhagic infarction and ventricular fibrillation. At 24 hr after 
reperfusion, dysrhythmias appeared to originate from multifocal ectopic sites in the 
saline-treated group. In the pranolium-pretreated animals, however, the severity of 
ventricular dysrhythmias was markedly reduced and abnormal beats appeared to be 
predominantly unifocal in origin and with a longer R-R interval. 
PRANOLIUM 187 
In control and pranolium-treated animals similar increases in ST-segment ele- 
vations were observed 15 min after LAD coronary artery occlusion. The devel- 
opment of pathologic Q-waves upon reperfusion, however, was significantly less 
in pranolium-treated animals versus controls. At 24 hr, pranolium-treated animals 
had evolved smaller Q-wave voltages compared with the control group. The sum 
of R-wave voltage decrease and the Q-wave voltage was significantly less in the 
drug-treated than in the control group. 
The loss of myocardial CPK activity, which has been used to quantitate the extent 
of myocardial infarction (3 1,45.73,75) was significantly less in pranolium-treated 
than in the control hearts. This suggests that pranolium treatment resulted in greater 
salvage of cardiac tissue in response to an ischemic insult. In these studies, infarct 
size, as measured gravimetrically after NBT staining, was reduced to a greater 
extent in pranolium-pretreated than in control animals. 
The available data show that pranolium protects the ischemic myocardium from 
irreversible injury. Pranolium was found to reduce myocardial infarct size, decrease 
voltage in the pathologic Q-wave, reduce the severity and number of premature 
ventricular contractions. and preserve myocardial CPK and dehydrogenase activities 
in hearts subjected to regional ischemia and reperfusion. 
Global Ischemia-Protective Effects of Pranolium 
Vogel et a]. (81) have examined the effect of pranolium on myocardial injury 
during global ischemia in the isolated and blood-perfused cat heart. This model 
was selected because the isolated preparation allows precise measurement and con- 
trol of hemodynamic viiriables, and global ischemia eliminates factors related to 
collateral coronary artery flow seen during regional ischemia. The use of the globally 
ischemic heart also simplifies tissue sampling problems associated with experimental 
models employing regional ischemic injury. Vogel el al. (81) studied several pa- 
rameters which have been associated with ischemic injury including the presence 
or absence of contracture, changes in ventricular pressure development and diastolic 
pressureivolume relationships, fluid and electrolyte accumulation, and microsomal 
Ca2+ accumulation. 
Four groups of isolated hearts were studied. A control group ( N  = 10) was not 
made ischemic and did not receive drug. A group of untreated ischemic hearts 
( N  = 10) was subjected to 1 hr of global ischemia followed by 1 hr of reperfusion. 
Two groups of ischemic hearts received pranolium (0.75 mg/min for 10 min) before 
ischemic arrest. In one group ( N  = lo), the hearts were allowed to beat sponta- 
neously during drug administration. The second group ( N  = 8) was paced at 150 
beats/min. 
During an infusion of pranolium to spontaneously beating isolated cat hearts 
(0.75 mg/min/lO min) lhere was a decrease in heart rate (135 k 12 to 85 f 9 
beatdmin), coronary blood flow (1.08 2 0.64 to 0.59 2 0.48 ml/min/g wet weight), 
and myocardial oxygen consumption (6.8 ? 1.7 to 2.7 f 1.7 ml/min/100 g wet 
weight). In hearts paced at 150 beats/min during pranolium infusion, ventricular 
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pulse pressure decreased 37% and this was similar to the decrease seen in unpaced 
hearts (Table 7). However, neither coronary blood flow nor oxygen consumption 
decreased in the paced hearts (Table 7), suggesting that the decrease in myocardial 
oxygen consumption seen in spontaneously beating hearts was a result of the neg- 
ative inotropic effect and not related to the contractile state of the myocardium 
under conditions in which left ventricular volume was maintained constant with a 
latex fluid-filled balloon. 
Pranolium decreased the severity of myocardial injury in response to global 
ischemia followed by reperfusion. Contracture during and immediately after global 
ischemia was decreased by pranolium pretreatment (Table 8) and, in addition, 
pranolium pretreatment maintained the ventricular diastolic pressure-volume rela- 
tionship at a level similar to that of the pre-ischemic control (Fig. 27). This suggests 
that pranolium protects the ventricle from the decrease in compliance normally seen 
after global ischemia. Pacing the heart at a constant rate during pranolium admin- 
istration partially reversed the protective effects of the drug on contracture and 
compliance, suggesting that the fall in heart rate produced by pranolium prior to 
the onset of ischemia is an important component of pranolium’s ability to reduce 
global ischemic injury (Fig. 27, Table 8). However, pranolium pretreatment was 
unable to produce any significant recovery in ventricular developed pressure. 
Besides its effect on the mechanical properties of ventricular muscle, pranolium 
reduced the reperfusion-induced hyperemic response at 60 min in nonpaced hearts 
(Fig, 28), decreased tissue accumulation of Na+ and Ca2+, and reduced K +  loss 
(Table 9). In addition, pranolium preserved both microsomal adenosine triphosphate 
(ATP)-dependent calcium uptake (Fig. 29) and calcium binding (Table 10). While 
the mechanism of ischemic contracture is controversial (30), it can be antagonized 
by manipulations which delay depletion of ATP or which may reduce the availability 
of calcium to contractile proteins (22). Warren et al. (83) have demonstrated that 
pranolium can reduce State 3 respiration, so that in the study of Vogel et al. (81), 
ATP stores may have been preserved by pranolium acting to decrease oxygen 
consumption independent of its negative chronotropic effect. Pranolium also reduced 
the augmentation of total myocardial calcium content (Table 9) which occurs upon 
reperfusion. Although it is not known how calcium was distributed within the 
myocardium in the pranolium-treated hearts, preservation of the calcium-accumu- 
lating ability of the sarcoplasmic reticulum may have maintained normal free calcium 
concentrations surrounding the contractile apparatus. 
While pranolium was not able to preserve all indices of myocardial function (i.e., 
developed ventricular pressure) the above study demonstrates that the quaternary 
drug can preserve myocardial viability during global ischemia by reducing my- 
ocardial energy requirements before ischemia and possibly through direct actions 
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TABLE 8. Development of confracture during ischemia8 
Ischemia Reperfusion 
10 min 20 min 30 min 40 min 50 min 60 min 5 min 
No Rx 2 ? 2  7 2 5  1 2 + . 1 0 1 6 2 9  1 9 k 9  2 5 2 8  3 2 k 1 0  
Pranolium 0 2 0  1 k 1  2 k 2  4 2 3 b  8 2 5 b  l l r 9 b  7 i 3 b  
Pranoliumkpace 0 2 0  1 k 2  2 k 3  4 k 4  7 2 6  1 2 ? 8 b  19211C 
Values are means k 95% confidence intervals. 
8Measured as increase in resting pressure, in millimeters of mercury, with left ventricular balloon 
bsignficantly different from value in untreated hearts. 
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FIG. 27. Summary of diastolic pressure-volume curves and left ventricular (LV) function curves. 
Diastolic pressure-volume curves are indicated by circles. Ventricular function curves were 
generated by plotting left ventricular pulse pressure as a function of left ventricular volume as 
indicated by the triangles. Solid symbols represent values obtained in the preischemic period; 
open symbols represent values obtained 1 hr after the end of the ischemic period. Each point 
represents the mean value of 8-10 hearts. Confidence intervals have been omitted for clarity. 
(From Vogel et al., ref. 81, with permission.) 
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FIG. 28. Coronary blood flow during the reperfusion period, with LVEDP adjusted to zero in 
all groups. Significant differences between ischemic hearts and nonischemic control hearts are 
indicated by ' ( p  < .005). The peak hyperemic response at 10 min of reperfusion was similar in 
all ischemic groups. At 60 min of reperfusion, coronary flow remained elevated in untreated 
hearts and in treated-paced hearts but returned toward control values in nonpaced treated 
hearts. At 60 min, flow in nonpaced, pranolium (UM-272)treated hearts was significantly less 
than in either of the other ischemic groups (p < ,001). Each bar represents the mean of 6-10 




Pranolium, in common with other monoquaternary ammonium compounds, is 
absorbed to a greater extent than could be predicted from its lipid solubility. Pran- 
olium is present in plasma within 10 min after oral administration of 40 or 60 mgikg 
to anesthetized dogs (59) (Fig. 30). As with other monoquaternary ammonium 
compounds (38), there is a nonlinear correlation between the dose administered and 
the amount absorbed. The extent of absorption of a 60-mg/kg dose of pranolium 
is about twice that of a 40-mg/kg dose, although both doses were sufficient to 
convert ouabain-induced ventricular tachycardia to normal sinus rhythm (59) (Fig. 
30). One possible explanation for the incomplete absorption of pranolium from the 
gastrointestinal tract is the presence of a monoquaternary ammonium ion transport 
system in jejunal mucosa (78). The transport system is capable of transporting 
monoquaternary ammonium ions from blood to the intestinal lumen and is saturable. 
The increased bioavailability of pranolium at a dose of 60 mg/kg versus 40 mg/kg 
may be the result of saturation of this intestinal transport system. 
Distribution 
Plasma concentrations of 14C-labeled pranolium decrease in a biexponential man- 
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FIG. 29. ATP-dependent 45Ca2+ uptake by microsomes isolated from cat hearts (N = 8-1 0) 
was measured in medium containing 0.1 M KCI; 5.6 mM MgCI,; 5.6 mM potassium oxalate; 100 
p . ~  45CaCI, (0.1 @/liter); 5 mM Tris-ATP; and 15 to 40 pg/ml of microsomal protein in 20 mM 
Tris-maleate buffer, pH 6.8 (37°C). Values shown are means ? 95% confidence limits, based 
upon duplicate runs, calculated for the four groups of isolated microsomes of cat hearts. Data 
are corrected for nonspecific binding of 45Ca2+ to Millipore filters. Inset: initial 2 min calcium 
uptake by cardiac microsomes isolated from the appropriate isolated hearts. With the exception 
of the ischemic-No Rx group, uptake proceeded linearly with time during this period. ’ ( p  < .05 
vs. control, pranolium (UM-272) and pranolium-paced); t ( p  < .02 vs. control, pranolium and 
pranolium-paced); $(p  < .05 vs. control). (From Vogel et al., ref. 81, with permission.) 
analysis indicates an alpha-phase distribution half-life of 2.1 t 0.2 min and a beta- 
phase distribution half-life of 127 t 10 min. The rapid clearance of pranolium 
from blood (approximately 11 mllminlkg) suggests that an active secretory process 
may be responsible for clearance of pranolium from plasma to urine. Approximately 
10% of an intravenously administered dose of I4C-labeled pranolium appears in 
urine at 2 hr after administration (16). Examination of urine samples by thin-layer 
chromatography failed to detect metabolites of pranolium. All 14C-labeled activity 
in urine migrated as a single peak which corresponded to reference 14C-labeled 
drug. 
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TABLE 10. Microsomal calcium binding 
Group 
~~ 
1 min %Control 5 min YO Control 
Control (6) 25 f. 10 100 48 k 15 100 
Ischemia-No Rx (6) 7 2  68 26 13 +- 12a 27 
Ischemia-Pranolium (4) 31 k 17 122 46 k 23 96 
Ischemia-Pranolium (6) (paced) 1 9 f .  10 74 38 k 3 79 
alndicates significant difference between untreated ischemic hearts and all other groups. 
Caz+ binding was assayed under conditions similar to those described in the legend to Fig. 
29 except that the 45Caz+ concentration was lowered to 20 JLM, protein concentration was 40- 
60 pgiml, the temperature was 25°C and potassium oxalate was absent from the incubation 
medium. Values are mean k 95% confidence limits. 
T 




FIG. 30. Plasma pranolium (UM- 
272) concentrations after p.0. admin- 
istration. Plasma pranolium concen- 
trations are shown for a period of 2 
hr. The area under the cuke was more 
than three times as great in the 60 
mg/kg group as the 40 mglkg group. 
(From Patterson et al., ref. 59, with 
permission.) 
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Pranolium exhibits a large steady-state volume of distribution, 1.6 liters/kg (16), 
suggesting that extensive binding of the drug occurs in body tissues. Pranolium 
concentrations in heart, diaphragm, skeletal muscle, and blood were determined 2 
hr after intravenous administration of 5 mg/kg I4C-labeled drug, and the data are 
presented in Fig. 31. Myocardial concentrations of pranolium were 36 times that 
of blood, 30 times that of skeletal muscle, and 5 times that of the diaphragm (16). 
Similar selective concentration of drug in heart tissue is observed after oral admin- 
istration of pranolium. Myocardial concentrations of pranolium after oral admin- 
istration of 40 or 60 mg/kg ranged from 8 to 35 times that of plasma (59). Table 
11 summarizes the data showing myocardial and plasma concentrations observed 
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FIG. 31. Pranolium concentrations in various tissues are shown 2 hr after administration. (From 
Gibson et al., ref. 16, with permission.) 
TABLE 11. Plasma and myocardial pranolium concentrations 2 hr after oral 
and intravenous administration 
Plasma Myocardium Urinary excretion 
(CLgiml) (lJ.g/ml) (“10 dose) 
5 mg/kg i.v. 1.0 % 0.2 Atrial 36.0 t 3.8 10.0 str 35% 
40 mg/kg p.0. 0.6 -t 0.1 Atrial 18.8 f 3.0 3.0 f 0.6% 
R. ventricle 34.3 i 6.7 
L. ventricle 36.4 str 1.9 
R. ventricle 18.8 2.9 
L. ventricle 18.9 ? 2.9 
R. ventricle 39.5 * 6.8 
L. ventricle 39.3 * 6.8 
60 mg/kg p.0. 0.9 t 0.5 Atrial 39.0 f 7.8 9.8 str 0.9% 
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Plasma Concentrations-Therapeutic Response 
Although plasma concentrations of pranolium decline rapidly after intravenous 
administration, a high concentration of pranolium is maintained in myocardium. 
The plasma concentration at the time of initial conversion of a oubain-induced 
ventricular tachycardia was 7.2 ? 1.5 p,g/ml, but despite its decrease to 1 .O t 0.2 
pg/ml2 hr later, the arrhythmia did not return. After oral administration, the plasma 
concentration of 4.2 -+ 1.5 pg/ml(60 mg/kg dose) and 0.7 AZ 0.2 pg/ml(40 mg/kg 
dose) were observed at the time of initial conversion of the ouabain-induced ven- 
tricular tachycardia to normal sinus rhythm. Lower plasma concentrations of 0.9 ? 0.5 
and 0.6 ? 0.1 p,g/ml were observed later in the experiment and still exerted sig- 
nificant antiarrhythmic action. Despite the presence of the lower plasma concen- 
trations 2 hr after administration of oral or intravenous pranolium, tissue concentrations 
remain high (Table 11) and the antiarrhythmic action persists. 
Duration of Action 
Despite the rapid clearance of pranolium from plasma, the extensive uptake of 
pranolium in heart tissue extends its duration of action beyond that which could be 
expected simply based upon plasma concentrations. Significant depression of con- 
duction in normal and ischemically injured myocardium and prolongation of ef- 
fective refractory periods in normal myocardium are observed 12 hr after a 5- or 
10-mg/kg dose. Protection against the induction of reentrant ventricular tachyar- 
rhythmias by programmed electrical stimulation was observed 12 hr after the last 
pranolium dose (62). 
Selective uptake and concentration in myocardium with a prolonged duration of 
action despite rapid clearance from plasma is seen also with bretylium (3 ,53) ,  
clofilium (39), and methyllidocaine (69,70). All three drugs are quaternary am- 
monium antifibrillatory agents that are cleared rapidly from plasma by renal mech- 
anisms (4,70), but have extended durations of action of up to 16 hr because of their 
ability to concentrate in myocardial tissue. 
SUMMARY 
In a wide variety of animal models, pranolium, the dimethyl quaternary derivative 
of propranolol, is effective in minimizing or eliminating the deleterious effects of 
myocardial ischemia. Pranolium reduces ultimate infarct size, decreases the extent 
of Q-wave and ST-segment changes attendant to ischemia, and reduces the accu- 
mulation of Ca2+ and contracture after global ischemia. Pranolium is also effective 
against both automatic and reentrant arrhythmias, and is effective in reducing mor- 
tality in a conscious canine model of sudden coronary death. Only one clinical 
study of pranolium has been performed to date and the results of this study are 
promising. Clearly, more clinical data as to the effectiveness of pranolium are 
needed and warranted as this drug may represent an important pharmacologic mo- 
dality in the prevention of cardiovascular death. Since the major cause of death is 
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sudden unexpected ventricular fibrillation in patients with recognized or unrecog- 
nized ischemic heart disease, there is an urgent need for a prophylactic agent that 
will exert an antifibrillatory action as opposed to an agent that suppresses premature 
ventricular ectopic beats-an action which may or may not coincide with an ability 
to prevent sudden coronary death. Pranolium, a quaternary ammonium compound 
without beta-adrenergic receptor blocking action, possesses both the antianhythmic 
and antifibrillatory actions which would recommend that its potential be explored 
further in patients who are at risk of sudden coronary death. Toxicology studies 
and preliminary clinical trials have provided further reason for being enthusiastic 
over the possibility that pranolium may serve a useful purpose in reducing the 
morbidity and mortality associated with ischemic heart disease. Furthermore, its 
effectiveness in several models of ischemic myocardial injury suggests that pran- 
olium has important potential applications in protecting the ischemic heart from 
irreversible cellular in.jury. The drug warrants further exploration at the clinical 
level in an effort to determine its full potential. 
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